MicroRNA are a group of non-coding RNA which, through regulating expression of proteins at post-transcription level, plays an important role in modulating growth and development of nervous system, cell differentiation and functions. Altered expression of microRNA in the brain may influence development and advance of Alzheimer's disease from multiple perspectives. Research on microRNA will facilitate in depth understanding of the pathogenesis of Alzheimer's disease.
Alzheimer Disease ; genetics ; metabolism ; Animals ; Humans ; MicroRNAs ; genetics ; metabolism

Alzheimer Disease ; metabolism ; Animals ; Antioxidants ; metabolism ; Mice ; Polysaccharides ; pharmacology

Alzheimer Disease ; genetics ; metabolism ; therapy ; Humans ; tau Proteins ; genetics ; metabolism

Dementia is a comprehensive category of brain diseases that is great enough to affect a person's daily functioning. The most common type of dementia is Alzheimer's disease, which makes most of cases. New researches indicate that gastrointestinal tract microbiota are directly linked to dementia pathogenesis through triggering metabolic diseases and low-grade inflammation progress. A novel strategy is proposed for the management of these disorders and as an adjuvant for psychiatric treatment of dementia and other related diseases through modulation of the microbiota (e.g. with the use of probiotics).
Alzheimer Disease ; metabolism ; microbiology ; physiopathology ; therapy ; Gastrointestinal Microbiome ; Humans

Humans ; Alzheimer Disease ; Cross-Sectional Studies ; Creatine Kinase ; Brain/metabolism*

OBJECTIVE: We hypothesized that prominent pulvinar hypointensity in brain MRI represents the disease process due to iron accumulation in Alzheimer disease (AD). We aimed to determine whether or not the pulvinar signal intensity (SI) on the fluid-attenuated inversion recovery (FLAIR) sequences at 3.0T MRI differs between AD patients and normal subjects, and also whether the pulvinar SI is correlated with the T2* map, an imaging marker for tissue iron, and a cognitive scale. MATERIALS AND METHODS: Twenty one consecutive patients with AD and 21 age-matched control subjects were prospectively included in this study. The pulvinar SI was assessed on the FLAIR image. We measured the relative SI ratio of the pulvinar to the corpus callosum. The T2* values were calculated from the T2* relaxometry map. The differences between the two groups were analyzed, by using a Student t test. The correlation between the measurements was assessed by the Pearson's correlation test. RESULTS: As compared to the normal white matter, the FLAIR signal intensity of the pulvinar nucleus was significantly more hypointense in the AD patients than in the control subjects (p < 0.01). The pulvinar T2* was shorter in the AD patients than in the control subjects (51.5 +/- 4.95 ms vs. 56.5 +/- 5.49 ms, respectively, p = 0.003). The pulvinar SI ratio was strongly correlated with the pulvinar T2* (r = 0.745, p < 0.001). When controlling for age, only the pulvinar-to-CC SI ratio was positively correlated with that of the Mini-Mental State Examination (MMSE) score (r = 0.303, p < 0.050). Conversely, the pulvinar T2* was not correlated with the MMSE score (r = 0.277, p = 0.080). CONCLUSION: The FLAIR hypointensity of the pulvinar nucleus represents an abnormal iron accumulation in AD and may be used as an adjunctive finding for evaluating AD.
Aged ; Alzheimer Disease/*metabolism/*pathology ; Female ; Humans ; Iron/*metabolism ; *Magnetic Resonance Imaging ; Male ; Pulvinar/metabolism/*pathology

The pathogenesis and treatment of Alzheimer's disease (AD) have developed into the frontier with the aging of people in the world. Meanwhile, they are the most difficult steps in the research on this degenerative disease of the nervous system. The over-deposition of beta-amyloid protein in nervous system is the most important feature. The formation and influencing factors of beta-amyloid protein are summarized in this paper. Furthermore, the methods and advance in treatment of AD are reviewed especially.
Aged ; Alzheimer Disease ; drug therapy ; metabolism ; Amyloid beta-Peptides ; metabolism ; Brain ; metabolism ; Humans ; Middle Aged

Triggering receptor expressed on myeloid cells 2 (TREM2) is a membrane receptor on myeloid cells and plays an important role in the body's immune defense. Recently, TREM2 has received extensive attention from researchers, and its activity has been found in Alzheimer's disease, neuroinflammation, and traumatic brain injury. The appearance of TREM2 is usually accompanied by changes in apolipoprotein E (ApoE), and there has been a lot of research into their structure, as well as the interaction mode and signal pathways involved in them. As two molecules with broad and important roles in the human body, understanding their correlation may provide therapeutic targets for certain diseases. In this article, we reviewed several diseases in which TREM2 and ApoE are synergistically involved in the development. We further discussed the positive or negative effects of the TREM2-ApoE pathway on nervous system immunity and inflammation.
Humans ; Alzheimer Disease/metabolism* ; Apolipoproteins E/genetics* ; Microglia/metabolism* ; Myeloid Cells/metabolism* ; Signal Transduction ; Neuroinflammatory Diseases

Extracellular deposition of β-amyloid (Aβ) and intracellular hyperphosphorylated tau are the predominant pathological changes in Alzheimer's disease (AD). Increasing evidence demonstrates a critical role of a variety of small GTPases, namely Ras-related proteins (Rabs), in the pathogenesis of AD. As crucial regulators of intracellular membrane trafficking, alteration in Rab protein expression and function represents one of the primary factors contributing to the abnormal membrane trafficking in AD. Additionally, the Rab GTPases are also involved in the development of Aβ, tau and other pathological changes associated with AD. In this article, we conduct a comprehensive review on the primary functions of multiple Rab proteins and their involvement in the pathogenesis of AD.
Humans ; Alzheimer Disease ; rab GTP-Binding Proteins/metabolism* ; Amyloid beta-Peptides/metabolism* ; tau Proteins/metabolism*

Alzheimer Disease ; metabolism ; therapy ; Amyloid beta-Peptides ; immunology ; metabolism ; Antibodies ; therapeutic use ; Humans ; Immunotherapy